Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

rituximab and modified (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Wisconsin, Madison
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• Untreated mantle cell lymphoma

Exclusion Criteria:

• Pregnant or breast feeding